Gilteritinib (brand name Xospata) is a medication used to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. It is a type of tyrosine kinase inhibitor, which works by blocking certain proteins in the body that may be involved in the growth of cancer cells. Gilteritinib is taken orally once daily. Common side effects include diarrhea, nausea, vomiting, and low white blood cell count.
Gilteritinib, sold under the brand name Xospata, is a medication used to treat a specific type of adult acute myeloid leukemia (AML) https://www.astellas.com/us/system/files/xospata.pdf. AML is a cancer of the blood and bone marrow. Gilteritinib is only effective for AML that has a specific genetic mutation called FLT3. A doctor will perform a test to see if this mutation is present before prescribing Gilteritinib.
Here's a breakdown of Gilteritinib:
- Type of drug: Tyrosine kinase inhibitor (TKI)
- What it targets: FLT3 protein (inhibits its activity)
- Conditions it treats: Relapsed or refractory (comes back or doesn't respond to treatment) FLT3-mutated AML in adults
- How it's given: Taken as a pill by mouth
Important things to know about Gilteritinib:
- It can cause serious side effects, including liver problems, fatigue, diarrhea, and differentiation syndrome (a rapid change in how the bone marrow makes blood cells).
- It is not known if Gilteritinib is safe and effective for children.
- There are medications and foods that can interact with Gilteritinib.
If you are considering Gilteritinib treatment, it is important to talk to your doctor about the risks and benefits. They can help you decide if this medication is right for you.
Here are some resources you can consult for more information:
- Xospata official patient site: https://www.astellas.com/us/system/files/xospata.pdf
- Gilteritinib on Wikipedia: https://en.wikipedia.org/wiki/Gilteritinib